CHU De Rouen
- Address
- 147 Avenue Du Marechal Juin, 76230 Bois-Guillaume, France
CHU De Rouen - Kidney Transplantation Research
CHU De Rouen is a leading clinical research institution specializing in advanced transplantation medicine, with particular expertise in kidney transplantation immunology. The center focuses on optimizing immunosuppressive strategies for complex patient populations, including sensitized transplant recipients who face increased risk of rejection.
- Induction therapy protocols in sensitized kidney transplant recipients
- Prevention of biopsy-proven acute rejection in transplantation
- Comparative studies of lymphocyte-depleting agents versus interleukin-2 receptor antagonists
The center's research emphasizes evidence-based approaches to managing immunological risk in kidney transplantation. Through multicenter randomized controlled trials, CHU De Rouen investigates novel strategies to prevent acute rejection while minimizing immunosuppression-related complications. Their work with sensitized patients without pre-existing donor-specific antibodies addresses a critical gap in transplant medicine, aiming to improve long-term graft survival and patient outcomes in this challenging population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU De Rouen
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease) | Hansa Biopharma AB | Phase III | Not Recruiting | May 2023 | Feb 2026 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Basiliximab | 1 | Unknown | 2023-11-07 | 2023-11-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.